Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.

Hdl Handle:
http://hdl.handle.net/10147/129670
Title:
Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.
Authors:
Byrne, A T; O'Connor, A E; Hall, M; Murtagh, J; O'Neill, K; Curran, K M; Mongrain, K; Rousseau, J A; Lecomte, R; McGee, S; Callanan, J J; O'Shea, D F; Gallagher, W M
Affiliation:
UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
Citation:
Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. 2009, 101 (9):1565-73 Br. J. Cancer
Journal:
British journal of cancer
Issue Date:
3-Nov-2009
URI:
http://hdl.handle.net/10147/129670
DOI:
10.1038/sj.bjc.6605247
PubMed ID:
19826417
Abstract:
Photodynamic therapy (PDT) is a treatment modality for a range of diseases including cancer. The BF(2)-chelated tetraaryl-azadipyrromethenes (ADPMs) are an emerging class of non-porphyrin PDT agent, which have previously shown excellent photochemical and photophysical properties for therapeutic application. Herein, in vivo efficacy and mechanism of action studies have been completed for the lead agent, ADMP06.; A multi-modality imaging approach was employed to assess efficacy of treatment, as well as probe the mechanism of action of ADPM06-mediated PDT.; Tumour ablation in 71% of animals bearing mammary tumours was achieved after delivery of 2 mg kg(-1) of ADPM06 followed immediately by light irradiation with 150 J cm(-2). The inherent fluorescence of ADPM06 was utilised to monitor organ biodistribution patterns, with fluorescence reaching baseline levels in all organs within 24 h. Mechanism of action studies were carried out using dynamic positron emission tomography and magnetic resonance imaging techniques, which, when taken together, indicated a decrease in tumour vascular perfusion and concomitant reduction in tumour metabolism over time after treatment.; The encouraging treatment responses in vivo and vascular-targeting mechanism of action continue to indicate therapeutic benefit for this new class of photosensitiser.
Item Type:
Article
Language:
en
MeSH:
Animals; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Female; Humans; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Photochemotherapy; Photosensitizing Agents; Positron-Emission Tomography; Pyrroles; Tissue Distribution
ISSN:
1532-1827

Full metadata record

DC FieldValue Language
dc.contributor.authorByrne, A Ten
dc.contributor.authorO'Connor, A Een
dc.contributor.authorHall, Men
dc.contributor.authorMurtagh, Jen
dc.contributor.authorO'Neill, Ken
dc.contributor.authorCurran, K Men
dc.contributor.authorMongrain, Ken
dc.contributor.authorRousseau, J Aen
dc.contributor.authorLecomte, Ren
dc.contributor.authorMcGee, Sen
dc.contributor.authorCallanan, J Jen
dc.contributor.authorO'Shea, D Fen
dc.contributor.authorGallagher, W Men
dc.date.accessioned2011-05-17T07:30:21Zen
dc.date.available2011-05-17T07:30:21Zen
dc.date.issued2009-11-03en
dc.identifier.citationVascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. 2009, 101 (9):1565-73 Br. J. Canceren
dc.identifier.issn1532-1827en
dc.identifier.pmid19826417en
dc.identifier.doi10.1038/sj.bjc.6605247en
dc.identifier.urihttp://hdl.handle.net/10147/129670en
dc.description.abstractPhotodynamic therapy (PDT) is a treatment modality for a range of diseases including cancer. The BF(2)-chelated tetraaryl-azadipyrromethenes (ADPMs) are an emerging class of non-porphyrin PDT agent, which have previously shown excellent photochemical and photophysical properties for therapeutic application. Herein, in vivo efficacy and mechanism of action studies have been completed for the lead agent, ADMP06.en
dc.description.abstractA multi-modality imaging approach was employed to assess efficacy of treatment, as well as probe the mechanism of action of ADPM06-mediated PDT.en
dc.description.abstractTumour ablation in 71% of animals bearing mammary tumours was achieved after delivery of 2 mg kg(-1) of ADPM06 followed immediately by light irradiation with 150 J cm(-2). The inherent fluorescence of ADPM06 was utilised to monitor organ biodistribution patterns, with fluorescence reaching baseline levels in all organs within 24 h. Mechanism of action studies were carried out using dynamic positron emission tomography and magnetic resonance imaging techniques, which, when taken together, indicated a decrease in tumour vascular perfusion and concomitant reduction in tumour metabolism over time after treatment.en
dc.description.abstractThe encouraging treatment responses in vivo and vascular-targeting mechanism of action continue to indicate therapeutic benefit for this new class of photosensitiser.en
dc.language.isoenen
dc.subject.meshAnimalsen
dc.subject.meshCell Line, Tumoren
dc.subject.meshCells, Cultureden
dc.subject.meshEndothelial Cellsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshMagnetic Resonance Imagingen
dc.subject.meshMammary Neoplasms, Experimentalen
dc.subject.meshMiceen
dc.subject.meshMice, Inbred C57BLen
dc.subject.meshPhotochemotherapyen
dc.subject.meshPhotosensitizing Agentsen
dc.subject.meshPositron-Emission Tomographyen
dc.subject.meshPyrrolesen
dc.subject.meshTissue Distributionen
dc.titleVascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.en
dc.typeArticleen
dc.contributor.departmentUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.en
dc.identifier.journalBritish journal of canceren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.